FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2395279537> ?p ?o ?g. }

• W2395279537 abstract "Background: BRCA1/2 mutation carriers (gBRCA) have a higher risk of breast or ovarian cancer, since BRCA1/2 mutation results in impaired high-fidelity DNA repair by homologous recombination (HR) and subsequently genetic instability. In non-gBRCA TNBC, HR deficiency occurs at the somatic level, by means of BRCA1 mutation, BRCA1 epigenetic loss or mutation in other HR-associated genes. Because PARP1/2 inhibitors (PARPi) are well-tolerated and active anti-cancer agents in the advanced setting of gBRCA tumors, we sought to expand their applicability by identifying response biomarkers in TNBC. Methods: We have assessed the antitumor response of the PARP1/2 inhibitor olaparib as single agent in a panel of 12 primary and advanced TNBC PDX models. On PDXs exhibiting primary sensitivity to olaparib, we have developed models of acquired resistance by continuous exposure to the drug and identifying progression on treatment. We have characterized the models through targeted sequencing and the analysis of the hypermethylation and expression levels of BRCA1 transcript to find potential correlates of drug-sensitivity. Results: Three out of 12 PDXs (25%) treated with single agent olaparib, exhibit tumor regression or disease stabilization. BRCA1 is hypermethylated in two of these PARPi-sensitive TNBC PDX models and is associated with loss of BRCA1 mRNA expression. The third PARPi-sensitive TNBC PDX harbors a frameshift, heterozygous PALB2 mutation, which is no longer detected in the acquired resistance PDX model. Acquired resistance in the hypermethylated PDXs is under study as well as the duration of response compared to gBRCA PDX models. Conclusions: Our study highlights that somatic HR-deficiency is frequent in TNBC and provides the basis of sensitivity to PARPi. Citation Format: Serra V, Cruz C, Bruna A, Ibrahim YH, Vivancos A, Vivancos A, Nuciforo P, Bellet M, Gomez P, Perez JM, Saura C, Vidal M, Serres X, Rueda OM, Peg V, Caldas C, O9Connor MJ, Baselga J, Cortes J. PARP1/2 inhibition in a subset of triple negative breast cancer (TNBC) patient-derived tumor xenografts (PDX) identifies predictive biomarkers of response. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-07-04." @default.
• W2395279537 created "2016-06-24" @default.
• W2395279537 creator A5004300577 @default.
• W2395279537 creator A5013805263 @default.
• W2395279537 creator A5017466693 @default.
• W2395279537 creator A5020244036 @default.
• W2395279537 creator A5020345162 @default.
• W2395279537 creator A5020966206 @default.
• W2395279537 creator A5021610360 @default.
• W2395279537 creator A5025238669 @default.
• W2395279537 creator A5052756445 @default.
• W2395279537 creator A5057381990 @default.
• W2395279537 creator A5061972017 @default.
• W2395279537 creator A5071581968 @default.
• W2395279537 creator A5071876778 @default.
• W2395279537 creator A5081053376 @default.
• W2395279537 creator A5081096983 @default.
• W2395279537 creator A5082195410 @default.
• W2395279537 creator A5089060804 @default.
• W2395279537 creator A5023443663 @default.
• W2395279537 date "2016-02-15" @default.
• W2395279537 modified "2023-09-26" @default.
• W2395279537 title "Abstract P4-07-04: PARP1/2 inhibition in a subset of triple negative breast cancer (TNBC) patient-derived tumor xenografts (PDX) identifies predictive biomarkers of response" @default.
• W2395279537 doi "https://doi.org/10.1158/1538-7445.sabcs15-p4-07-04" @default.
• W2395279537 hasPublicationYear "2016" @default.
• W2395279537 type Work @default.
• W2395279537 sameAs 2395279537 @default.
• W2395279537 citedByCount "0" @default.
• W2395279537 crossrefType "proceedings-article" @default.
• W2395279537 hasAuthorship W2395279537A5004300577 @default.
• W2395279537 hasAuthorship W2395279537A5013805263 @default.
• W2395279537 hasAuthorship W2395279537A5017466693 @default.
• W2395279537 hasAuthorship W2395279537A5020244036 @default.
• W2395279537 hasAuthorship W2395279537A5020345162 @default.
• W2395279537 hasAuthorship W2395279537A5020966206 @default.
• W2395279537 hasAuthorship W2395279537A5021610360 @default.
• W2395279537 hasAuthorship W2395279537A5023443663 @default.
• W2395279537 hasAuthorship W2395279537A5025238669 @default.
• W2395279537 hasAuthorship W2395279537A5052756445 @default.
• W2395279537 hasAuthorship W2395279537A5057381990 @default.
• W2395279537 hasAuthorship W2395279537A5061972017 @default.
• W2395279537 hasAuthorship W2395279537A5071581968 @default.
• W2395279537 hasAuthorship W2395279537A5071876778 @default.
• W2395279537 hasAuthorship W2395279537A5081053376 @default.
• W2395279537 hasAuthorship W2395279537A5081096983 @default.
• W2395279537 hasAuthorship W2395279537A5082195410 @default.
• W2395279537 hasAuthorship W2395279537A5089060804 @default.
• W2395279537 hasConcept C104317684 @default.
• W2395279537 hasConcept C121608353 @default.
• W2395279537 hasConcept C126322002 @default.
• W2395279537 hasConcept C13514818 @default.
• W2395279537 hasConcept C143998085 @default.
• W2395279537 hasConcept C182979987 @default.
• W2395279537 hasConcept C2778144015 @default.
• W2395279537 hasConcept C2778480876 @default.
• W2395279537 hasConcept C2779138821 @default.
• W2395279537 hasConcept C2779962180 @default.
• W2395279537 hasConcept C2780110267 @default.
• W2395279537 hasConcept C2780427987 @default.
• W2395279537 hasConcept C29906990 @default.
• W2395279537 hasConcept C501734568 @default.
• W2395279537 hasConcept C502942594 @default.
• W2395279537 hasConcept C530470458 @default.
• W2395279537 hasConcept C54355233 @default.
• W2395279537 hasConcept C71924100 @default.
• W2395279537 hasConcept C82381507 @default.
• W2395279537 hasConcept C86803240 @default.
• W2395279537 hasConceptScore W2395279537C104317684 @default.
• W2395279537 hasConceptScore W2395279537C121608353 @default.
• W2395279537 hasConceptScore W2395279537C126322002 @default.
• W2395279537 hasConceptScore W2395279537C13514818 @default.
• W2395279537 hasConceptScore W2395279537C143998085 @default.
• W2395279537 hasConceptScore W2395279537C182979987 @default.
• W2395279537 hasConceptScore W2395279537C2778144015 @default.
• W2395279537 hasConceptScore W2395279537C2778480876 @default.
• W2395279537 hasConceptScore W2395279537C2779138821 @default.
• W2395279537 hasConceptScore W2395279537C2779962180 @default.
• W2395279537 hasConceptScore W2395279537C2780110267 @default.
• W2395279537 hasConceptScore W2395279537C2780427987 @default.
• W2395279537 hasConceptScore W2395279537C29906990 @default.
• W2395279537 hasConceptScore W2395279537C501734568 @default.
• W2395279537 hasConceptScore W2395279537C502942594 @default.
• W2395279537 hasConceptScore W2395279537C530470458 @default.
• W2395279537 hasConceptScore W2395279537C54355233 @default.
• W2395279537 hasConceptScore W2395279537C71924100 @default.
• W2395279537 hasConceptScore W2395279537C82381507 @default.
• W2395279537 hasConceptScore W2395279537C86803240 @default.
• W2395279537 hasLocation W23952795371 @default.
• W2395279537 hasOpenAccess W2395279537 @default.
• W2395279537 hasPrimaryLocation W23952795371 @default.
• W2395279537 hasRelatedWork W10138567 @default.
• W2395279537 hasRelatedWork W12171474 @default.
• W2395279537 hasRelatedWork W12293262 @default.
• W2395279537 hasRelatedWork W16746045 @default.
• W2395279537 hasRelatedWork W17538324 @default.
• W2395279537 hasRelatedWork W19122808 @default.
• W2395279537 hasRelatedWork W2908475 @default.
• W2395279537 hasRelatedWork W3598312 @default.
• W2395279537 hasRelatedWork W6390110 @default.
• W2395279537 hasRelatedWork W18975889 @default.

• next